| Id: | acc1166 |
| Group: | 2sens |
| Protein: | S6 |
| Gene Symbol: | Rps6 |
| Protein Id: | P62755 |
| Protein Name: | RS6_RAT |
| PTM: | phosphorylation |
| Site: | Ser236 |
| Site Sequence: | QIAKRRRLSSLRASTSKSESS |
| Disease Category: | Gynecological diseases |
| Disease: | Uterine Leiomyomas |
| Disease Subtype: | LM |
| Disease Cellline: | ELT-3 |
| Disease Info: | |
| Drug: | metformin |
| Drug Info: | "Metformin is an oral antihyperglycemic agent used primarily in the treatment of type 2 diabetes, which works by reducing hepatic glucose production and enhancing peripheral insulin sensitivity." |
| Effect: | modulate |
| Effect Info: | "Metformin induces the phosphorylation of AMPK and simultaneously reduces the phosphorylation of S6 protein, thereby inhibiting leiomyoma cells." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 22835064 |
| Sentence Index: | 22835064_8-9 |
| Sentence: | "Western blotting analysis demonstrated that metformin induced phosphorylation of AMPK and the inhibitory effect was attenuated with AMPK inhibitor, compound C. In parallel, treatment with metformin decreased phosphorylation of S6 protein. These experimental findings show that metformin is a potent inhibitor of cell proliferation in leiomyoma cells." |
Sequence & Structure:
MKLNISFPATGCQKLIEVDDERKLRTFYEKRMATEVAADALGEEWKGYVVRISGGNDKQGFPMKQGVLTHGRVRLLLSKGHSCYRPRRTGERKRKSVRGCIVDANLSVLNLVIVKKGEKDIPGLTDTTVPRRLGPKRASRIRKLFNLSKEDDVRQYVVRKPLNKEGKKPRTKAPKIQRLVTPRVLQHKRRRIALKKQRTKKNKEEAAEYAKLLAKRMKEAKEKRQEQIAKRRRLSSLRASTSKSESSQK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | P | Ascites hepatoma | Phosphorylation | 2852063 |
| - | - | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 6319390 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
